TABLE OF CONTENTS
1 EXECUTIVE SUMMARY
2 MARKET INTRODUCTION
2.1 DEFINITION
2.2 SCOPE OF THE STUDY
2.3 RESEARCH OBJECTIVE
2.4 MARKET STRUCTURE
3 RESEARCH METHODOLOGY
3.1 OVERVIEW
3.2 DATA FLOW
3.2.1 Data Mining Process
3.3 PURCHASED DATABASE:
3.4 SECONDARY SOURCES:
3.4.1 Secondary Research data flow:
3.5 PRIMARY RESEARCH:
3.5.1 Primary Research Data Flow:
3.5.2 Primary Research: Number Of Interviews Conducted
3.6 APPROACHES FOR MARKET SIZE ESTIMATION:
3.6.1 Revenue Analysis Approach
3.7 DATA FORECASTING
3.7.1 Data Forecasting Technique
3.8 DATA MODELLING
3.8.1 Microeconomic Factor Analysis:
3.8.2 Data Modelling:
3.9 TEAMS AND ANALYST CONTRIBUTION
4 MARKET DYNAMICS
4.1 INTRODUCTION
4.2 DRIVERS
4.2.1 Increasing Prevalence Of Diabetes And Preference For Non-Insulin Therapies
4.2.2 Cardiovascular Protection Alongside Diabetic Control
4.3 RESTRAINTS
4.3.1 Side Effects Associated with GLP-1 Drugs
4.4 OPPORTUNITY
4.4.1 Development Of Next-Generation Therapies And Growing Focus On Patient-Centric Solutions
4.4.2 Development Of New Applications And Treatment For Obesity Management
5 MARKET FACTOR ANALYSIS
5.1 PORTER'S FIVE FORCES MODEL
5.1.1 Threat of New Entrants
5.1.2 Bargaining Power Of Suppliers
5.1.3 Threat of Substitutes
5.1.4 Bargaining Power of Buyers
5.1.5 Intensity of Rivalry
5.2 IMPACT OF COVID-19 ON THE GLP-1 DRUG MARKET
6 GLP-1 DRUG MARKET, BY TYPE
6.1 OVERVIEW
6.2 Long-acting GLP-1 Drug
6.3 Short-acting GLP-1 Drug
7 GLP-1 DRUG MARKET, BY APPLICATION
7.1 OVERVIEW
7.2 Type 2 Diabetes (T2DM)
7.3 Obesity
7.4 Non-alcoholic Steatohepatitis (NASH)
7.5 Alzheimer's Disease (AD)
7.6 Cardiovascular and Cerebrovascular Diseases (CVD)
8 GLP-1 DRUG MARKET, BY ROUTE OF ADMINISTRATION
8.1 OVERVIEW
8.2 Parenteral
8.3 Oral
9 GLP-1 DRUG MARKET, BY DISTRIBUTION CHANNEL
9.1 OVERVIEW
9.2 Retail Pharmacies
9.3 Hospitals Pharmacies
9.4 Online Pharmacies
10 GLP-1 DRUG MARKET, BY REGION
10.1 OVERVIEW
10.2 North America
10.2.1 US
10.2.2 Canada
10.3 Europe
10.3.1 Germany
10.3.2 France
10.3.3 UK
10.3.4 Italy
10.3.5 Spain
10.3.6 Rest of Europe
10.4 Asia Pacific
10.4.1 China
10.4.2 Japan
10.4.3 India
10.4.4 South Korea
10.4.5 Australia
10.4.6 Rest of Asia Pacific
10.5 Rest of World
10.5.1 Middle East
10.5.2 Africa
10.5.3 Latin America
11 COMPETITIVE LANDSCAPE
11.1 INTRODUCTION
11.2 MARKET SHARE ANALYSIS, 2022
11.3 COMPETITOR DASHBOARD
11.4 PUBLIC PLAYERS STOCK SUMMARY
11.5 COMPARATIVE ANALYSIS: KEY PLAYERS FINANICAL
11.6 KEY DEVELOPMENTS & GROWTH STRATEGIES
11.6.1 Product Approval
12 COMPANY PROFILES
12.1 ELI LILLY AND COMPANY
12.1.1 COMPANY OVERVIEW
12.1.2 FINANCIAL OVERVIEW
12.1.3 PRODUCTS OFFERED
12.1.4 KEY DEVELOPMENTS
12.1.5 SWOT ANALYSIS
12.1.6 KEY STRATEGIES
13.2 ASTRAZENECA
13.2.1 COMPANY OVERVIEW
13.2.2 FINANCIAL OVERVIEW
13.2.3 PRODUCTS OFFERED
13.2.4 KEY DEVELOPMENTS
13.2.5 KEY STRATEGIES
14.3 PFIZER
14.3.1 COMPANY OVERVIEW
14.3.2 FINANCIAL OVERVIEW
14.3.3 PRODUCTS OFFERED
14.3.4 KEY DEVELOPMENTS
14.3.5 KEY STRATEGIES
15.4 SANOFI
15.4.1 COMPANY OVERVIEW
15.4.2 FINANCIAL OVERVIEW
15.4.3 PRODUCTS OFFERED
15.4.4 KEY DEVELOPMENTS
15.4.5 SWOT ANALYSIS
15.4.6 KEY STRATEGIES
16.5 GSK
16.5.1 COMPANY OVERVIEW
16.5.2 FINANCIAL OVERVIEW
16.5.3 Products OFFERed
16.5.4 KEY DEVELOPMENTS
16.5.5 KEY STRATEGIES
17.6 NOVO NORDISK
17.6.1 COMPANY OVERVIEW
17.6.2 FINANCIAL OVERVIEW
17.6.3 Products OFFERed
17.6.4 KEY DEVELOPMENTS
17.6.5 KEY STRATEGIES
18.7 GAN & LEE PHARMACEUTICALS
18.7.1 COMPANY OVERVIEW
18.7.2 FINANCIAL OVERVIEW
18.7.3 Products OFFERed
18.7.4 KEY DEVELOPMENTS
18.7.5 KEY STRATEGIES
19.8 BOEHRINGER INGELHEIM
19.8.1 COMPANY OVERVIEW
19.8.2 FINANCIAL OVERVIEW
19.8.3 productS OFFERED
19.8.4 KEY DEVELOPMENTS
19.8.5 SWOT ANALYSIS
19.8.6 KEY STRATEGIES
20.9 TONGHUA DONGBAO PHARMACEUTICAL CO., LTD.
20.9.1 COMPANY OVERVIEW
20.9.2 FINANCIAL OVERVIEW
20.9.3 products OFFERED
20.9.4 KEY DEVELOPMENTS
20.9.5 SWOT ANALYSIS
20.9.6 KEY STRATEGIES
21.10 JIANGSU HANSOH PHARMACEUTICAL GROUP CO., LTD.
21.10.1 COMPANY OVERVIEW
21.10.2 FINANCIAL OVERVIEW
21.10.3 products OFFERED
21.10.4 KEY DEVELOPMENTS
21.10.5 SWOT ANALYSIS
21.10.6 KEY STRATEGIES
22.11 SHANGHAI RENHUI BIOPHARMACEUTICAL CO., LTD.
22.11.1 COMPANY OVERVIEW
22.11.2 FINANCIAL OVERVIEW
22.11.3 products OFFERED
22.11.4 KEY DEVELOPMENTS
22.11.5 SWOT ANALYSIS
22.11.6 KEY STRATEGIES
23.12 SHANGHAI EAST CHINA PHARMACEUTICAL MACHINERY CO., LTD.
23.12.1 COMPANY OVERVIEW
23.12.2 FINANCIAL OVERVIEW
23.12.3 products OFFERED
23.12.4 KEY DEVELOPMENTS
23.12.5 SWOT ANALYSIS
23.12.6 KEY STRATEGIES
12 DATA CITATIONS
LIST OF TABLES
TABLE 1 QFD MODELLING FOR MARKET SHARE ASSESSMENT
TABLE 2 GLP-1 DRUG MARKET, BY TYPE, 2019–2032 (USD BILLION)
TABLE 3 GLP-1 DRUG MARKET, BY APPLICATION, 2019–2032 (USD BILLION)
TABLE 4 GLP-1 DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2019–2032 (USD BILLION)
TABLE 5 GLP-1 DRUG MARKET, BY DISTRIBUTION CHANNEL, 2019–2032 (USD BILLION)
TABLE 7 GLP-1 DRUG MARKET, BY REGION, 2019–2032 (USD BILLION)
TABLE 8 PUBLIC PLAYERS STOCK SUMMARY
TABLE 9 COMPARATIVE ANALYSIS: KEY PLAYERS FINANICAL
TABLE 10 PRODUCT APPROVAL
TABLE 11 ELI LILLY AND COMPANY: PRODUCTS OFFERED
TABLE 12 ASTRAZENECA: PRODCUTS OFFERED
TABLE 13 PFIZER: PRODUCTS OFFERED
TABLE 14 SANOFI: PRODUCTS OFFERED
TABLE 15 GSK: PRODUCTS OFFERED
TABLE 16 NOVO NORDISK: PRODUCTS OFFERED
TABLE 17 GAN & LEE PHARMACEUTICALS.: PRODUCTS OFFERED
TABLE 18 BOEHRINGER INGELHEIM: PRODUCTS OFFERED
TABLE 19 TONGHUA DONGBAO PHARMACEUTICAL CO., LTD.: PRODUCTS OFFERED
TABLE 20 JIANGSU HANSOH PHARMACEUTICAL GROUP CO., LTD.: PRODUCTS OFFERED
TABLE 21 SHANGHAI RENHUI BIOPHARMACEUTICAL CO., LTD.: PRODUCTS OFFERED
TABLE 22 SHANGHAI EAST CHINA PHARMACEUTICAL MACHINERY CO., LTD.: PRODUCTS OFFERED
LIST OF FIGURES
FIGURE 1 GLP-1 DRUG MARKET: STRUCTURE
FIGURE 2 GLP-1 DRUG MARKET REPORT: MARKET GROWTH FACTOR ANALYSIS (2022-2032)
FIGURE 3 DRIVER IMPACT ANALYSIS (2023-2032)
FIGURE 4 RESTRAINT IMPACT ANALYSIS (2022-2032)
FIGURE 5 PORTER'S FIVE FORCES ANALYSIS: GLP-1 DRUG MARKET
FIGURE 6 GLP-1 DRUG MARKET, TYPE SEGMENT ATTRACTIVENESS, 2019-2032 (USD BILLION)
FIGURE 7 GLP-1 DRUG MARKET, BY TYPE, 2019 & 2032 (USD BILLION)
FIGURE 8 GLP-1 DRUG MARKET SHARE (%), BY TYPE, 2023
FIGURE 10 GLP-1 DRUG MARKET, BY APPLICATION, 2019 & 2032 (USD BILLION)
FIGURE 11 GLP-1 DRUG MARKET SHARE (%), BY APPLICATION, 2023
FIGURE 12 GLP-1 DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2019 & 2032 (USD BILLION)
FIGURE 13 GLP-1 DRUG MARKET SHARE (%), BY ROUTE OF ADMINISTRATION, 2023
FIGURE 14 GLP-1 DRUG MARKET, BY DISTRIBUTION CHANNEL, 2019 & 2032 (USD BILLION)
FIGURE 15 GLP-1 DRUG MARKET SHARE (%), BY DISTRIBUTION CHANNEL, 2023
FIGURE 16 GLP-1 DRUG MARKET, BY REGION, 2019 & 2032 (USD BILLION)
FIGURE 17 GLP-1 DRUG MARKET SHARE (%), BY REGION, 2023
FIGURE 18 GLP-1 DRUG MARKET PLAYERS: COMPETITIVE ANALSIS, 2023
FIGURE 19 COMPETITOR DASHBOARD: GLP-1 DRUG MARKET
FIGURE 20 ELI LILLY AND COMPANY: FINANCIAL OVERVIEW
FIGURE 21 ELI LILLY AND COMPANY: SWOT ANALYSIS
FIGURE 22 ASTRAZENECA: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 23 ASTRAZENECA: SWOT ANALYSIS
FIGURE 24 PFIZER: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 25 PFIZER: SWOT ANALYSIS
FIGURE 26 SANOFI.: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 27 SANOFI: SWOT ANALYSIS
FIGURE 28 GSK: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 29 GSK: SWOT ANALYSIS
FIGURE 30 NOVO NORDISK: FINANCIAL OVERVIEW
FIGURE 31 NOVO NORDISK: SWOT ANALYSIS
FIGURE 32 GAN & LEE PHARMACEUTICALS: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 33 GAN & LEE PHARMACEUTICALS: SWOT ANALYSIS
FIGURE 34 BOEHRINGER INGELHEIM: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 35 BOEHRINGER INGELHEIM: SWOT ANALYSIS
FIGURE 36 TONGHUA DONGBAO PHARMACEUTICAL CO., LTD.: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 37 TONGHUA DONGBAO PHARMACEUTICAL CO., LTD.: SWOT ANALYSIS
FIGURE 38 JIANGSU HANSOH PHARMACEUTICAL GROUP CO., LTD.: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 39 JIANGSU HANSOH PHARMACEUTICAL GROUP CO., LTD.: SWOT ANALYSIS
FIGURE 40 SHANGHAI RENHUI BIOPHARMACEUTICAL CO., LTD.: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 41 SHANGHAI RENHUI BIOPHARMACEUTICAL CO., LTD.: SWOT ANALYSIS
FIGURE 42 SHANGHAI EAST CHINA PHARMACEUTICAL MACHINERY CO., LTD.: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 43 SHANGHAI EAST CHINA PHARMACEUTICAL MACHINERY CO., LTD.: SWOT ANALYSIS
